Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT AMNEAL PHARMACEUTICALS, INC.

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
Listen to this Section


$13.84
+0.3150 ( +2.33% ) 517.4K

Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Market Data


Open $13.84
Previous Close $13.52
Volume 517.4K
Market Cap $4.31B
Day Range $13.58 - $13.88
52 Week Range $7.07 - $15.42
Shares Outstanding 319.02M
Change % +2.33%
Net Change ▲ 0.3150
Insider Ownership -0.02%
Exchange NASDAQ
SectorMiscellaneous
IndustryNone
IPO Year2018
CountryUnited States

Insider Ownership Transactions

Total Amount Purchased: -274,493.00

Date Type Amount Purchased Purchaser
2024-05-20 Sale -14553.00 Autor Deborah M.
2024-05-14 Sale -107034.00 MEISTER PAUL M
2024-05-14 Sale -76453.00 Autor Deborah M.
2024-05-14 Sale -76453.00 Alva Emily Peterson

SEC Filings


Form Type Description Pages Date
10-q Quarterly Reports 105 Nov 06, 2025
8-k 8K-related 14 Oct 30, 2025
4 Insider transactions 1 Aug 28, 2025
4 Insider transactions 1 Aug 25, 2025
4 Insider transactions 1 Aug 22, 2025
4 Insider transactions 1 Aug 15, 2025
4 Insider transactions 1 Aug 15, 2025
4 Insider transactions 1 Aug 13, 2025
4 Insider transactions 1 Aug 13, 2025
4 Insider transactions 1 Aug 13, 2025

Latest News


× Before browsing our site, please accept our cookies policy